HaleonHLN
About: Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Employees: 24,622
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
358% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $770K
39% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 67
27% more capital invested
Capital invested by funds: $5.5B [Q3] → $7B (+$1.5B) [Q4]
15% more repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 174
3% more funds holding
Funds holding: 578 [Q3] → 594 (+16) [Q4]
2.4% more ownership
Funds ownership: 5.71% [Q3] → 8.11% (+2.4%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for HLN.
Financial journalist opinion
Based on 8 articles about HLN published over the past 30 days
